Switch to:
Also traded in: Germany, Japan

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.84
ESALY's Cash to Debt is ranked lower than
66% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. ESALY: 0.84 )
Ranked among companies with meaningful Cash to Debt only.
ESALY' s Cash to Debt Range Over the Past 10 Years
Min: 0.3  Med: 0.65 Max: N/A
Current: 0.84
Equity to Asset 0.59
ESALY's Equity to Asset is ranked lower than
55% of the 701 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. ESALY: 0.59 )
Ranked among companies with meaningful Equity to Asset only.
ESALY' s Equity to Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.43 Max: 0.6
Current: 0.59
0.37
0.6
Interest Coverage 13.44
ESALY's Interest Coverage is ranked lower than
61% of the 461 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.94 vs. ESALY: 13.44 )
Ranked among companies with meaningful Interest Coverage only.
ESALY' s Interest Coverage Range Over the Past 10 Years
Min: 5.79  Med: 12.96 Max: 1619.43
Current: 13.44
5.79
1619.43
F-Score: 6
Z-Score: 4.39
M-Score: -2.67
WACC vs ROIC
5.83%
7.23%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 9.38
ESALY's Operating margin (%) is ranked higher than
52% of the 708 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.77 vs. ESALY: 9.38 )
Ranked among companies with meaningful Operating margin (%) only.
ESALY' s Operating margin (%) Range Over the Past 10 Years
Min: 2.42  Med: 12.01 Max: 15.92
Current: 9.38
2.42
15.92
Net-margin (%) 7.97
ESALY's Net-margin (%) is ranked higher than
55% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.28 vs. ESALY: 7.97 )
Ranked among companies with meaningful Net-margin (%) only.
ESALY' s Net-margin (%) Range Over the Past 10 Years
Min: -2.32  Med: 8.19 Max: 10.55
Current: 7.97
-2.32
10.55
ROE (%) 7.57
ESALY's ROE (%) is ranked higher than
52% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.97 vs. ESALY: 7.57 )
Ranked among companies with meaningful ROE (%) only.
ESALY' s ROE (%) Range Over the Past 10 Years
Min: -3.4  Med: 10.87 Max: 16.4
Current: 7.57
-3.4
16.4
ROA (%) 4.42
ESALY's ROA (%) is ranked higher than
54% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. ESALY: 4.42 )
Ranked among companies with meaningful ROA (%) only.
ESALY' s ROA (%) Range Over the Past 10 Years
Min: -1.78  Med: 4.58 Max: 9.24
Current: 4.42
-1.78
9.24
ROC (Joel Greenblatt) (%) 23.13
ESALY's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 757 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.44 vs. ESALY: 23.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ESALY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 7.99  Med: 30.74 Max: 56.21
Current: 23.13
7.99
56.21
Revenue Growth (3Y)(%) -5.50
ESALY's Revenue Growth (3Y)(%) is ranked lower than
78% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. ESALY: -5.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ESALY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 6.00 Max: 12
Current: -5.5
0
12
EBITDA Growth (3Y)(%) -22.60
ESALY's EBITDA Growth (3Y)(%) is ranked lower than
87% of the 545 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. ESALY: -22.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ESALY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 3.20 Max: 45
Current: -22.6
0
45
EPS Growth (3Y)(%) -9.60
ESALY's EPS Growth (3Y)(%) is ranked lower than
74% of the 501 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. ESALY: -9.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ESALY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -17.3  Med: 7.10 Max: 53.8
Current: -9.6
-17.3
53.8
» ESALY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ESALY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 43.55
ESALY's P/E(ttm) is ranked lower than
69% of the 542 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.66 vs. ESALY: 43.55 )
Ranked among companies with meaningful P/E(ttm) only.
ESALY' s P/E(ttm) Range Over the Past 10 Years
Min: 12.4  Med: 23.61 Max: 119.42
Current: 43.55
12.4
119.42
PE(NRI) 43.44
ESALY's PE(NRI) is ranked lower than
69% of the 539 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.62 vs. ESALY: 43.44 )
Ranked among companies with meaningful PE(NRI) only.
ESALY' s PE(NRI) Range Over the Past 10 Years
Min: 12.4  Med: 23.61 Max: 119.43
Current: 43.44
12.4
119.43
Price/Owner Earnings (ttm) 22.84
ESALY's Price/Owner Earnings (ttm) is ranked higher than
69% of the 259 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.02 vs. ESALY: 22.84 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ESALY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.31  Med: 18.06 Max: 32.45
Current: 22.84
10.31
32.45
P/B 3.27
ESALY's P/B is ranked lower than
56% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. ESALY: 3.27 )
Ranked among companies with meaningful P/B only.
ESALY' s P/B Range Over the Past 10 Years
Min: 1.76  Med: 2.29 Max: 4.2
Current: 3.27
1.76
4.2
P/S 3.45
ESALY's P/S is ranked lower than
58% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. ESALY: 3.45 )
Ranked among companies with meaningful P/S only.
ESALY' s P/S Range Over the Past 10 Years
Min: 0.96  Med: 1.72 Max: 6.6
Current: 3.45
0.96
6.6
PFCF 33.93
ESALY's PFCF is ranked lower than
57% of the 192 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.79 vs. ESALY: 33.93 )
Ranked among companies with meaningful PFCF only.
ESALY' s PFCF Range Over the Past 10 Years
Min: 5.75  Med: 19.08 Max: 206.63
Current: 33.93
5.75
206.63
POCF 20.25
ESALY's POCF is ranked lower than
57% of the 251 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.79 vs. ESALY: 20.25 )
Ranked among companies with meaningful POCF only.
ESALY' s POCF Range Over the Past 10 Years
Min: 4.92  Med: 12.71 Max: 69.65
Current: 20.25
4.92
69.65
EV-to-EBIT 35.78
ESALY's EV-to-EBIT is ranked lower than
75% of the 525 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.51 vs. ESALY: 35.78 )
Ranked among companies with meaningful EV-to-EBIT only.
ESALY' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.4  Med: 16.30 Max: 85.2
Current: 35.78
9.4
85.2
EV-to-EBITDA 21.30
ESALY's EV-to-EBITDA is ranked lower than
61% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.66 vs. ESALY: 21.30 )
Ranked among companies with meaningful EV-to-EBITDA only.
ESALY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.4  Med: 9.40 Max: 36.6
Current: 21.3
6.4
36.6
Current Ratio 2.60
ESALY's Current Ratio is ranked higher than
54% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. ESALY: 2.60 )
Ranked among companies with meaningful Current Ratio only.
ESALY' s Current Ratio Range Over the Past 10 Years
Min: 1.85  Med: 2.28 Max: 2.81
Current: 2.6
1.85
2.81
Quick Ratio 2.17
ESALY's Quick Ratio is ranked higher than
58% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. ESALY: 2.17 )
Ranked among companies with meaningful Quick Ratio only.
ESALY' s Quick Ratio Range Over the Past 10 Years
Min: 1.58  Med: 1.91 Max: 2.37
Current: 2.17
1.58
2.37
Days Inventory 154.89
ESALY's Days Inventory is ranked lower than
69% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. ESALY: 154.89 )
Ranked among companies with meaningful Days Inventory only.
ESALY' s Days Inventory Range Over the Past 10 Years
Min: 146.81  Med: 158.37 Max: 170.66
Current: 154.89
146.81
170.66

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.97
ESALY's Dividend Yield is ranked higher than
70% of the 565 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.56 vs. ESALY: 1.97 )
Ranked among companies with meaningful Dividend Yield only.
ESALY' s Dividend Yield Range Over the Past 10 Years
Min: 1.7  Med: 4.15 Max: 6.71
Current: 1.97
1.7
6.71
Dividend Payout 0.94
ESALY's Dividend Payout is ranked lower than
90% of the 371 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.35 vs. ESALY: 0.94 )
Ranked among companies with meaningful Dividend Payout only.
ESALY' s Dividend Payout Range Over the Past 10 Years
Min: 0.48  Med: 1.66 Max: 1000
Current: 0.94
0.48
1000
Forward Dividend Yield 1.81
ESALY's Forward Dividend Yield is ranked higher than
70% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. ESALY: 1.81 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.98
ESALY's Yield on cost (5-Year) is ranked higher than
57% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.98 vs. ESALY: 1.98 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ESALY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.7  Med: 4.15 Max: 6.71
Current: 1.98
1.7
6.71
3-Year Average Share Buyback Ratio -0.10
ESALY's 3-Year Average Share Buyback Ratio is ranked higher than
79% of the 466 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -3.30 vs. ESALY: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ESALY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.1  Med: 0.00 Max: 0
Current: -0.1
-0.1
0

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 44.65
ESALY's Price/Net Current Asset Value is ranked lower than
94% of the 428 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.81 vs. ESALY: 44.65 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ESALY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 34.61  Med: 61.00 Max: 244.85
Current: 44.65
34.61
244.85
Price/Tangible Book 6.57
ESALY's Price/Tangible Book is ranked lower than
75% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. ESALY: 6.57 )
Ranked among companies with meaningful Price/Tangible Book only.
ESALY' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.21  Med: 6.24 Max: 18.51
Current: 6.57
4.21
18.51
Price/Projected FCF 1.72
ESALY's Price/Projected FCF is ranked higher than
65% of the 300 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. ESALY: 1.72 )
Ranked among companies with meaningful Price/Projected FCF only.
ESALY' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.05  Med: 1.19 Max: 2.12
Current: 1.72
1.05
2.12
Price/Median PS Value 2.01
ESALY's Price/Median PS Value is ranked lower than
79% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. ESALY: 2.01 )
Ranked among companies with meaningful Price/Median PS Value only.
ESALY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.59  Med: 1.04 Max: 3.31
Current: 2.01
0.59
3.31
Price/Graham Number 3.56
ESALY's Price/Graham Number is ranked lower than
74% of the 446 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.09 vs. ESALY: 3.56 )
Ranked among companies with meaningful Price/Graham Number only.
ESALY' s Price/Graham Number Range Over the Past 10 Years
Min: 1.87  Med: 2.52 Max: 4.61
Current: 3.56
1.87
4.61
Earnings Yield (Greenblatt) (%) 2.80
ESALY's Earnings Yield (Greenblatt) (%) is ranked lower than
53% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. ESALY: 2.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ESALY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.2  Med: 6.10 Max: 10.6
Current: 2.8
1.2
10.6
Forward Rate of Return (Yacktman) (%) -12.93
ESALY's Forward Rate of Return (Yacktman) (%) is ranked lower than
83% of the 316 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.27 vs. ESALY: -12.93 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ESALY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -13.6  Med: 3.50 Max: 22.4
Current: -12.93
-13.6
22.4

More Statistics

Revenue(Mil) $5067
EPS $ 1.40
Beta-0.27
Short Percentage of Float0.00%
52-Week Range $55.81 - 71.86
Shares Outstanding(Mil)285.61

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:AGN, NYSE:TEVA, TSE:4502, BOM:524715, NYSE:ZTS, NAS:MYL » details
Traded in other countries:EII.Germany, 4523.Japan,
Eisai Co Ltd was incorporated in Japan on December 6, 1941. It is a pharmaceutical company engaged in manufacturing and marketing of prescription medicines and over-the-counter products. The Company operates in five geographical segments including; Japan Pharmaceutical Business, Americas Pharmaceutical Business, Asia Pharmaceutical Business, EMEA Pharmaceutical Business, and Consumer Healthcare Business - Japan. The Japan Pharmaceutical Business is engaged in the sales of prescription drugs, generic drugs and diagnostics in Japan. The Americas Pharmaceutical Business is engaged in the development and marketing of Oncology-Related Products & Epilepsy Products. The Asia Pharmaceutical Business is engaged in selling Oncology-Related Products, Aricept, Pariet/AcipHex, and Epilepsy Products in Asia including China, South Korea, Taiwan, India and ASEAN nations. The EMEA Pharmaceutical Business sells Epilepsy Products, Oncology-Related Products, Aricept, & Pariet/AcipHex in Europe, the Middle East, Africa, Russia and Oceania. The Consumer Healthcare Business - Japan is engaged in the sale of Chocola BB group of products in Japan.
» More Articles for ESALY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Aricept Approved in the Philippines for New Indication as Treatment for Dementia with Lewy Bodies Apr 13 2016
Eisai and PharmStandard Sign Cooperation Agreements in Russia Apr 05 2016
Eisai Receives Positive CHMP Opinion on New Indicator for Anticancer Agent Halaven for Treatment of... Apr 04 2016
Dr. Reddy's Acquires Anticancer Drug Rights from Eisai Apr 01 2016
Dr. Reddy’s Laboratories Acquires the Rights to Investigational Anticancer Agent E7777 for U.S.,... Mar 31 2016
Eisai Transfer the Rights to Investigational Anticancer Agent E7777 for European, U.S and Certain... Mar 31 2016
Eisai's Notice Concerning Shelf Registration for Issuance of Stock Options Mar 30 2016
Eisai Co., Ltd. and Ajinomoto Co., Inc. Announce Establishment of Gastrointestinal Specialty Pharma... Mar 30 2016
Eisai's Notification Regarding Revision of Consolidated Financial Results Forecasts (IFRS) for the... Mar 30 2016
Global Drug Maker Eisai Signs Three-Year Contract Extension For CSC’s Total Regulatory Solution... Mar 30 2016
Eisai's In-House Developed Antiepileptic Drug Fycompa (Perampanel Hydrate) Approved in Japan Mar 28 2016
Eisai Withdraws New Drugs Application for Mecobalamin Ultra-High Dose Preparation as Treatment for... Mar 22 2016
Notice Regarding Discontinuation of Sales and Voluntary Recall of Egg White Lysozyme Preparation... Mar 17 2016
Lenvima® (lenvatinib) Now Available in Israel as Important New Treatment for People with Advanced... Mar 08 2016
Eisai Co., Ltd. :ESALY-US: Earnings Analysis: Q3, 2016 By the Numbers Mar 04 2016
Eisai Co., Ltd. :ESALY-US: Earnings Analysis: Q3, 2016 By the Numbers Mar 04 2016
Eisai Co., Ltd. :ESALY-US: Earnings Analysis: Q3, 2016 By the Numbers Mar 03 2016
Will Arena (ARNA) Post a Narrower-than-Expected 4Q Loss? Feb 26 2016
Eisai Slams the New Cancer Drug Fund that Further Delays Patient Access to New Cancer Drug Feb 25 2016
Eisai and PIQUR Sign Landmark Collaboration Agreement to Investigate Halaven® (Eribulin) and PQR309... Feb 16 2016
Eisai and Sysmex Enter Comprehensive Agreement to Create Next-Generation Diagnostic Reagents in the... Feb 15 2016
Eisai and Charles River Laboratories Announce Collaboration for New Drug Discovery Feb 14 2016
Phase III Trial Results of Eisai's Anticancer Agent Halaven(R) in Soft Tissue Sarcoma Published in... Feb 11 2016
Eisai Co., Ltd. Earnings Analysis: Q3, 2016 By the Numbers Feb 08 2016
Eisai and Esteve Sign New Agreement to Co-promote Anti-epilepsy Drug Fycompa® (Perampanel) in Spain Feb 03 2016
Eisai Acquires Exclusive License from Huya Bioscience International to Develop and Market HDAC... Feb 01 2016
Eisai Submits New Application in Europe for In-House Developed Anticancer Agent Lenvatinib Seeking... Jan 12 2016
Lenvima® (lenvatinib) Now Reimbursed for Advanced Thyroid Cancer in Sweden Dec 15 2015
MHLW Approves Partial Label Change for Egg-White Lysozyme Preparation Neuzym Dec 10 2015
Arena (ARNA)/Eisai's Belviq XR NDA Accepted for Review Dec 01 2015
Eisai and Toyama Chemical Clear All-Case Surveillance Condition for Approval of Antirheumatic Agent... Dec 01 2015
U.S. FDA Accepts NDA for Once-Daily Formulation of Antiobesity Agent Belviq Nov 30 2015
FEZ and EWJ Stocks Trading above Moving Averages Nov 25 2015
Successful Ruling in Patent Infringement Litigation for Antiemetic Agent Aloxi in the United States Nov 17 2015
Arena 3Q Loss Narrower-Than-Expected, Belviq in Focus Nov 11 2015
Eisai to Commence Two Joint Research Programs toward Development of New Antimalarial Medicines Nov 05 2015
Eisai Co., Ltd. Earnings Q2, 2016 Nov 02 2015
Eisai Co., Ltd. – Value Analysis (US OTC:ESALY) : October 22, 2015 Oct 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK